Table 1 Demographic and CSF biomarker data.
From: Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer’s disease
CN (n = 44) | DLB (n = 37) | Prodromal DLB (n = 23) | AD (n = 50) | Prodromal AD (n = 53) | Total | p-value | ||
|---|---|---|---|---|---|---|---|---|
Age, y ± SD (range)a | 67.4 ± 5.1 (60.2–78.7) | 76.5 ± 5 (64–84.6) | 76.5 ± 6.4 (58.5–85.8) | 74.6 ± 5.6 (62.4–86.8) | 72.3 ± 6.3 (60.4–85) | 73 ± 6.5 (58.5–86–8) | <0.001 | |
Sex, Female % (n) | 56.8 (25) | 54.1 (20) | 56.5 (13) | 62 (31) | 60.4 (32) | 57.8% (78) | 0.949 | |
APOEε4, %* (n)b | 18.2 (8) | 24.3 (9) | 34.8 (8) | 58 (29) | 75 (39) | 45.1 (93) | 0.003 | |
MMSE ± SDc | 28.9 ± 1.2 | 23 ± 4.6 | 26.1 ± 2.4 | 22.5 ± 3.4 | 26.7 ± 2.3 | 25.7 ± 3.8 | <0.001 | |
Core AD biomarkers | CSF Aβ1–42, pg/mL ± SDd | 918.2 ± 212.2 | 602.7 ± 269.2 | 634 ± 197.7 | 384.7 ± 105.6 | 458.1 ± 72.2 | 583.6 ± 261 | <0.001 |
CSF t-tau, pg/mL ± SDe | 228.8 ± 52.3 | 448.9 ± 333.9 | 371.3 ± 174.5 | 694.5 ± 321 | 609 ± 267.7 | 493.8 ± 310 | <0.001 | |
CSF p-tau, pg/mL ± SDf | 45.5 ± 10.2 | 68.8 ± 42.3 | 62.6 ± 24.4 | 94.1 ± 26.2 | 94.8 ± 39.2 | 76 ± 36.8 | <0.001 | |
Inflammation-related biomarkers | CSF YKL-40, ng/mL ± SDg | 238.8 ± 49.2 | 278.8 ± 83.4 | 270.7 ± 69 | 295.3 ± 54.1 | 296.7 ± 55.7 | 277.8 ± 64.8 | <0.001 |
CSF sTREM2, ng/mL ± SD (n)h | 4.2 ± 2.3 (40) | 5.3 ± 2.3 (28) | 4.4 ± 1.9 (18) | 4.3 ± 2.2 (36) | 5 ± 2.4 (41) | 4.6 ± 2.3 (163) | 0.038 | |
CSF PGRN, ng/mL ± SD | 4.3 ± 1.2 | 4.2 ± 1.1 | 4.5 ± 1.3 | 4.4 ± 1.3 | 4.6 ± 1.2 | 4.4 ± 1.2 | 0.653 |
